Stock Futures Decline as Oil Prices Rise Above $105
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Stock futures are pointing lower ahead of the open, signaling a weaker start to the session. The decline follows a sharp move higher in oil, with Brent crude pushing back above $105 per barrel after Iran rejected ceasefire proposals and tensions around the Strait of Hormuz intensified. Markets are firmly back in risk-off mode as the brief relief trade from earlier in the week gives way to renewed escalation in the Middle East and a fresh surge in energy prices.Global equities are lower across Asia and Europe, reversing the recent rebound, while the dollar is strengthening and gold is failing to attract consistent safe-haven demand. This combination points to tightening financial conditions rather than a typical defensive rotation. Bond markets also are showing signs of stress, with rising volatility and weaker liquidity conditions, indicating that the impact is no longer isolated to equities.In pre-market trading, S&P 500 futures fell 0.93%, Nasdaq futures fell 1.13% and Dow futures fell 0.83%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Kodiak Sciencesup 50% after reporting its GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy met its primary and secondary endpointsCorebridgeand Equitable Holdingsboth up 1% after the companies announced that they have entered into a definitive agreement to combine in an all-stock merger, valuing the combined company at approximately $22BUP AFTER EARNINGS -Noodles & Companyup 19%Navanup 19%Lovesacup 12%DOWN AFTER EARNINGS -MillerKnolldown 21%Worthington Steeldown 14%Designer Brandsdown 9%Commercial Metalsdown 3%
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KOD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KOD
Wall Street analysts forecast KOD stock price to fall
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 36.120
Low
14.00
Averages
27.86
High
50.00
Current: 36.120
Low
14.00
Averages
27.86
High
50.00
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kodiak Sciences CEO to Present at Jefferies Global Healthcare Conference
- Presentation Schedule: Kodiak Sciences CEO Victor Perlroth, M.D. will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access critical information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal diseases, committed to researching and commercializing transformative therapeutics aimed at addressing the leading causes of blindness globally, showcasing its innovative potential in the healthcare sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its robust capabilities and promising market outlook in retinal drug development.
See More
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Kodiak Sciences CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access the information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal therapeutics, committed to researching and commercializing transformative therapies aimed at preventing and treating leading causes of blindness globally, showcasing its innovative capabilities in the biotech sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its strong expertise and market potential in retinal drug development.
See More
Boxer Capital Increases Stake in Kodiak Sciences Amid Strong Performance
- Stake Increase: Boxer Capital Management increased its stake in Kodiak Sciences by 225,000 shares during Q1 2026, with an estimated transaction value of $5.81 million, indicating strong confidence in the company's future prospects.
- Market Performance: As of May 14, 2026, Kodiak Sciences shares were priced at $38.70, reflecting a staggering 1,000% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its potential.
- Financial Position: Kodiak Sciences reported a market value of $51.88 million at the end of Q1, despite a quarterly net loss of $58.2 million; however, the company has $169.5 million in cash, which is expected to fund operations into 2027.
- Clinical Developments: The company is set to announce several clinical trial results, including top-line data for wet AMD in September, and positive outcomes could further drive stock price increases, attracting more investor interest.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Kodiak Sciences Showcases KSI-101 Clinical Advances
- Clinical Data Consistency: KSI-101 demonstrated rapid and significant visual and anatomical improvements in the U.S. Phase 1b APEX study, with over 50% of patients achieving ≥15-letter gains, and consistent results were observed in the Asian clinical cohort, supporting its potential for global development.
- International Conference Presentations: Kodiak will showcase six poster presentations at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, highlighting KSI-101's clinical progress and applicability across diverse patient populations, thereby enhancing its market recognition.
- New Therapy Development: In addition to KSI-101, Kodiak is advancing KSI-102 and KSI-103, two novel biologic therapies designed to address complex cytokine interactions in chronic inflammatory ocular diseases, showcasing the company's innovative capabilities in the ophthalmic field.
- Market Potential: The development of KSI-101 targets the approximately one million patients affected by macular edema annually, expected to fill the current market gap for effective biologics, presenting significant commercial value and societal impact.
See More
KSI-101 Clinical Results Support Global Development
- Clinical Consistency: KSI-101's results in Asian clinical trials align closely with those from the U.S. Phase 1b APEX study, with 58% of patients achieving a ≥15-letter improvement in visual acuity over 24 weeks, indicating its applicability across diverse patient populations and supporting further global development.
- Multi-Target Therapy Advancement: Kodiak is advancing KSI-102 and KSI-103, novel bispecific therapies designed to address complex cytokine interactions in chronic ocular inflammatory diseases, suggesting significant potential for enhanced therapeutic outcomes beyond current single-target therapies.
- ABCD Platform Innovation: The evolving ABCD platform from Kodiak integrates small molecules and other drugs, showcasing its potential for targeted, multi-modal drug development in retinal and glaucoma optic neuropathy, which could transform the landscape of ocular treatments.
- International Conference Presentations: Kodiak will present its clinical advancements at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, enhancing collaboration and engagement with peers to deepen scientific research and development efforts.
See More
Kodiak Sciences CEO to Present at Jefferies Global Healthcare Conference
- Presentation Schedule: Kodiak Sciences CEO Victor Perlroth, M.D. will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access critical information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal diseases, committed to researching and commercializing transformative therapeutics aimed at addressing the leading causes of blindness globally, showcasing its innovative potential in the healthcare sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its robust capabilities and promising market outlook in retinal drug development.
See More
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Kodiak Sciences CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access the information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal therapeutics, committed to researching and commercializing transformative therapies aimed at preventing and treating leading causes of blindness globally, showcasing its innovative capabilities in the biotech sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its strong expertise and market potential in retinal drug development.
See More
Boxer Capital Increases Stake in Kodiak Sciences Amid Strong Performance
- Stake Increase: Boxer Capital Management increased its stake in Kodiak Sciences by 225,000 shares during Q1 2026, with an estimated transaction value of $5.81 million, indicating strong confidence in the company's future prospects.
- Market Performance: As of May 14, 2026, Kodiak Sciences shares were priced at $38.70, reflecting a staggering 1,000% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its potential.
- Financial Position: Kodiak Sciences reported a market value of $51.88 million at the end of Q1, despite a quarterly net loss of $58.2 million; however, the company has $169.5 million in cash, which is expected to fund operations into 2027.
- Clinical Developments: The company is set to announce several clinical trial results, including top-line data for wet AMD in September, and positive outcomes could further drive stock price increases, attracting more investor interest.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Kodiak Sciences Showcases KSI-101 Clinical Advances
- Clinical Data Consistency: KSI-101 demonstrated rapid and significant visual and anatomical improvements in the U.S. Phase 1b APEX study, with over 50% of patients achieving ≥15-letter gains, and consistent results were observed in the Asian clinical cohort, supporting its potential for global development.
- International Conference Presentations: Kodiak will showcase six poster presentations at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, highlighting KSI-101's clinical progress and applicability across diverse patient populations, thereby enhancing its market recognition.
- New Therapy Development: In addition to KSI-101, Kodiak is advancing KSI-102 and KSI-103, two novel biologic therapies designed to address complex cytokine interactions in chronic inflammatory ocular diseases, showcasing the company's innovative capabilities in the ophthalmic field.
- Market Potential: The development of KSI-101 targets the approximately one million patients affected by macular edema annually, expected to fill the current market gap for effective biologics, presenting significant commercial value and societal impact.
See More
KSI-101 Clinical Results Support Global Development
- Clinical Consistency: KSI-101's results in Asian clinical trials align closely with those from the U.S. Phase 1b APEX study, with 58% of patients achieving a ≥15-letter improvement in visual acuity over 24 weeks, indicating its applicability across diverse patient populations and supporting further global development.
- Multi-Target Therapy Advancement: Kodiak is advancing KSI-102 and KSI-103, novel bispecific therapies designed to address complex cytokine interactions in chronic ocular inflammatory diseases, suggesting significant potential for enhanced therapeutic outcomes beyond current single-target therapies.
- ABCD Platform Innovation: The evolving ABCD platform from Kodiak integrates small molecules and other drugs, showcasing its potential for targeted, multi-modal drug development in retinal and glaucoma optic neuropathy, which could transform the landscape of ocular treatments.
- International Conference Presentations: Kodiak will present its clinical advancements at the 2026 American Uveitis Society and Association for Research in Vision and Ophthalmology meetings, enhancing collaboration and engagement with peers to deepen scientific research and development efforts.
See More
